{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-107154","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.071964+00:00","generated_at":"2026-05-15T11:52:15.678838+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Olema reports FY2025 net loss of $162.5M; cash $505.4M; OPERA-01 data fall 2026","bullets":["Net loss Q4 $46.1M, full year $162.5M; R&D expenses $43.2M and $157.7M respectively.","Cash and marketable securities $505.4M; raised $218.5M in public offering.","Phase 3 OPERA-01 top-line data expected fall 2026; Phase 1b/2 with Pfizer atirmociclib initiated.","OP-3136 initial clinical data expected Q2 2026; commercial launch prep for potential late 2027 approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-107154","json":"https://secwatch.observer/filing/0001193125-26-107154.json","markdown":"https://secwatch.observer/filing/0001193125-26-107154.md","text":"https://secwatch.observer/filing/0001193125-26-107154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526107154/0001193125-26-107154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526107154/olma-20260316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:52:15.678838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"97204863b67cd96406274f16e4a5fec6cd53f3af","claim":"Olema Pharmaceuticals, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss for the quarter and year ended December 31, 2025 was $46.1 million and $162.5 million, respectively.","evidence_excerpt":"On March 16, 2026, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526107154/0001193125-26-107154-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Net income","value":"Net loss for the quarter and year ended December 31, 2025 was $46.1 million and $162.5 million, respectively"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}